



GUJARAT ROAD AND INFRASTRUCTURE COMPANY LIMITED

Registered Office : Office of the Secretary, Roads & Buildings Department, Block 14, Second Floor, Sachivalaya, Gandhinagar - 382 019

CIN: U65990GJ1999PLC036068

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022 (IN R Lakhs)

Sr. No.	Particulars	Quarter ended		Nine months ended		Previous Year Ended (Audited)
		Dec. 31, 2022 (Unaudited)	Sept. 30, 2022 (Unaudited)	Dec. 31, 2021 (Unaudited)	Dec. 31, 2021 (Unaudited)	
1.	Total Income from Operations	7,832	7,086	7,131	21,813	16,216
2.	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	5,480	4,735	4,129	14,704	7,831
3.	Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	5,480	4,735	4,129	14,704	7,831
4.	Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	3,881	3,364	3,861	10,409	7,330
5.	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	3,881	3,365	3,857	10,410	7,327
6.	Paid up Equity Share Capital	5,546	5,546	5,546	5,546	5,546
7.	Reserves (excluding Revaluation Reserve)					40,628
8.	Net worth					46,175
9.	Paid up Debt Capital / Outstanding Debt	14,537	14,522	16,973	14,537	16,973
10.	Debt Equity Ratio	0.29	0.31	0.40	0.29	0.40
11.	Basic and diluted earnings per share (EPS) (Face value of INR 10/- each) (not annualised for the quarter and nine months)					
	- Basic	7.00	6.07	6.96	18.77	13.22
	- Diluted	7.00	6.07	6.96	18.77	13.22
12.	Capital Redemption Reserve	3,500	3,500	3,500	3,500	3,500
13.	Debt Service Coverage Ratio	1,475	1,600	1,265	1,475	1,265
14.	Debt Service Coverage Ratio	15.06	3.09	10.43	6.44	3.51
15.	Interest Service Coverage Ratio	15.06	12.29	10.43	13.01	6.73

NOTES TO THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

- The above is an extract of the detailed format of quarterly and nine months ended financial results filed with the Stock Exchanges under Regulation 52 of the Listing Regulations. The full format of the quarterly and nine months ended financial results are available on the websites of the Stock Exchange - National Stock Exchange (NSE) websites www.nseindia.com and Company's website www.gicrl.com
- (2) For the items referred in the Regulation 52 (4) of the SEBI (Listing and Disclosure Requirements) Regulations, 2015 (as amended), the pertinent disclosures have been made to the Stock Exchange (NSE) and can be accessed on the (www.nseindia.com) and on the Company's website www.gicrl.com
- (3) The unaudited standalone financial results for the quarter ended June 30, 2021 as included in the unaudited standalone financial results for the nine months period April 1, 2021 to December 31, 2021 have not been subjected to audit or review by our statutory auditors. However, the management has exercised necessary diligence to ensure that the figures for the said quarter provide a true and fair view of the Company's affairs.

Date: February 09, 2023

Place: Gandhinagar

For and on behalf of the Board
Chief Executive Officer

"IMPORTANT"

Whilst care is taken prior to acceptance of advertising copy, it is not possible to verify its contents. The Indian Express (P) Limited cannot be held responsible for such contents, nor for any loss or damage incurred as a result of transactions with companies, associations or individuals advertising in its newspapers or Publications. We therefore recommend that readers make necessary inquiries before sending any monies or entering into any agreements with advertisers or otherwise acting on an advertisement in any manner whatsoever.

RUCHIRA PAPERS LIMITED

Regd. Office: Tirlokpur Road, Kala Amb, District-Sirmaur-H.P-173030

Website: www.ruchirapapers.com,

Email: cs@ruchirapapers.com, investor@ruchirapapers.com

CIN: L21012HP1980PLC004336

EXTRACT OF UN-AUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31ST DECEMBER 2022

S.No	Particulars	Rs.(In Lakhs) except Earning per Share				
		31.12.2022	30.09.2022	31.12.2021	31.12.2022	31.12.2021
1	Total Income from Operations (net)	20286.59	22149.21	14864.42	62352.56	42293.02
2	Net Profit for the period (before tax and exceptional items)	2311.35	2663.53	790.53	6539.89	2280.61
3	Net Profit for the period before tax (after exceptional and/or extraordinary items)	2311.35	2663.53	790.53	6539.89	2280.61
4	Net Profit for the period (after tax after exceptional items)	1724.31	1989.01	585.73	4876.75	1697.83
5	Total comprehensive income for the period	1717.26	1949.34	593.57	4827.36	1657.81
6	Paid up Equity Share Capital	2984.5	2713.18	2520.43	2984.50	2520.43
7	Other Equity (as shown in the Audited Balance Sheet of Previous Year)			-	-	28438.61
8	Earnings per share (of Rs. 10/- each) Not annualised					
	(a) Basic	5.78	7.33	2.42	16.34	6.74
	(b) Diluted	5.78	7.33	2.28	16.34	6.62

The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the stock exchange websites, at a link (<http://www.bseindia.com/#corporates>) and (<https://www.nseindia.com/corporates>) and on the Company's website at www.ruchirapapers.com

For and on behalf of Board of Directors
Umesh Chander Garg
Managing Director

PHARMASIA LIMITED

Registered Office: 16, Phase-III, IDA, Jeedimetla, Hyderabad - 500055 Telangana, India.

Tel. No.: +91-040-23095690 | Fax No.: +91-040-23097323 | Email id: pharmaisagrd@gmail.com

Website: www.pharmasia.in | Contact Person: Mrs. Urvashi Bhatia, Company Secretary & Compliance Officer

Corporate Identification Number (CIN): L24239TG1981PLC002915

Recommendations of the Committee of Independent Directors ("IDC") of Pharmasia Limited (the "Company"), on the Delisting Offer made by Maneesh Pharmaceuticals Limited ("Promoter Acquirer"), along with other member of the Promoter and Promoter Group of the Company ("Delisting Offer"), to the public shareholders of the Company under Regulations 28 and other applicable provisions of the Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2021, as amended ("the SEBI Delisting Regulations").

1	Date of meeting of IDC	Thursday, February 09, 2023
2	Name of the Company	Pharmasia Limited
3	Details of the Delisting Offer pertaining to the Company	Voluntary Delisting Offer made by the Promoter Acquirer, along with other members of promoter and promoter group, to acquire 18,08,228 Equity shares representing 26.49% of the paid-up capital of the Company from the Public Shareholders and consequently, voluntarily delist equity shares of the Company from BSE Limited ("BSE") (referred to as "Stock Exchange") pursuant to the SEBI Delisting Regulations.
	Floor Price:	₹ 24 per Equity Share
	Indicative Price:	₹ 25 per Equity Share
	Methodology for Delisting:	Through Reverse Book Building process
	The IDC reviewed the following:	
	a.	Initial Public Announcement dated November 11, 2022 (the "IPA");
	b.	Detailed Public Announcement published on February 06, 2023, (the "DPA"); and c. Letter of Offer dated February 06, 2023 (the "LOF")

4	Name of the Acquirer and PAC with the acquirer	Maneesh Pharmaceuticals Limited along with promoter and promoter group. There are no PAC's with the Promoter Acquirer for the purpose of Offer.
5	Name of the Manager to the Offer	Saffron Capital Advisors Private Limited

6	Members of the Committee of Independent Directors (IDC)	Name of Independent Director Position in Committee
	1) Pravin Mohandas Hedge	Chairman
	2) Ajit Gopal Jamkhandikar	Member

7	IDC Member's relationship with the Company (Director, Equity shares owned, any other contract / relationship, if any)	The IDC Chairman and the member are Independent Directors on the Board of Directors of the Company.
		The IDC Chairman and the member neither hold any equity shares in the Company nor do they have any contract/relationship with the Company.

8	Trading in the Equity shares/other securities of the Company by IDC Members	The IDC Chairman and the member have not traded in any of the Equity Shares/other securities of the Company:
		(i) during the 12 (twelve) months period preceding the date of the IPA and;
		(ii) during the period between the date of the IPA and the date of this recommendation (i.e. February 09, 2023)

9	IDC Member's relationship with the acquirer	a. The IDC Chairman and the member are Independent directors on the Board of the Promoter Acquirer.
		b. The IDC Chairman and the member do not hold any equity shares or other securities of the Promoter Acquirer.
		c. The IDC Chairman and the member do not have any contracts/relationship with the Promoter Acquirer, except the directorship as mentioned in point (a) above.

10	Trading in the Equity shares/other securities of the acquirer by IDC Members	The Equity shares/other securities of the Promoter Acquirer are not listed on any of the stock exchanges in India and abroad.
		Further, the IDC Chairman and the member of IDC neither hold any equity shares in the Promoter Acquirer nor have traded in any of the equity/other securities of the Promoter Acquirer during the 12 (twelve) month period preceding the date of the IPA.

11	Recommendation on the delisting offer, as to whether the offer, is fair and reasonable	Based on the review of the IPA, DPA and LOF issued by Saffron Capital Advisors Private Limited, Manager to the Delisting Offer, on behalf of Promoter Acquirer, the IDC Chairman and the member of the IDC recommend that:
</tr